MX2021007063A - Deutetrabenazina para el tratamiento de la discinesia en la paralisis cerebral. - Google Patents

Deutetrabenazina para el tratamiento de la discinesia en la paralisis cerebral.

Info

Publication number
MX2021007063A
MX2021007063A MX2021007063A MX2021007063A MX2021007063A MX 2021007063 A MX2021007063 A MX 2021007063A MX 2021007063 A MX2021007063 A MX 2021007063A MX 2021007063 A MX2021007063 A MX 2021007063A MX 2021007063 A MX2021007063 A MX 2021007063A
Authority
MX
Mexico
Prior art keywords
deutetrabenazine
dyskinesia
cerebral palsy
treatment
directed
Prior art date
Application number
MX2021007063A
Other languages
English (en)
Spanish (es)
Inventor
Frank Schneider
Mark Forrest Gordon
Juha- Matti SAVOLA
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of MX2021007063A publication Critical patent/MX2021007063A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021007063A 2018-12-13 2019-12-13 Deutetrabenazina para el tratamiento de la discinesia en la paralisis cerebral. MX2021007063A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779232P 2018-12-13 2018-12-13
US201962801450P 2019-02-05 2019-02-05
PCT/US2019/066150 WO2020123900A1 (en) 2018-12-13 2019-12-13 Deutetrabenazine for the treatment of dyskinesia in cerebral palsy

Publications (1)

Publication Number Publication Date
MX2021007063A true MX2021007063A (es) 2021-12-10

Family

ID=69173404

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007063A MX2021007063A (es) 2018-12-13 2019-12-13 Deutetrabenazina para el tratamiento de la discinesia en la paralisis cerebral.

Country Status (15)

Country Link
US (3) US11324732B2 (cg-RX-API-DMAC7.html)
EP (1) EP3893876A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022519007A (cg-RX-API-DMAC7.html)
KR (1) KR20210114946A (cg-RX-API-DMAC7.html)
CN (1) CN113395966A (cg-RX-API-DMAC7.html)
AU (1) AU2019395250A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021011386A2 (cg-RX-API-DMAC7.html)
CA (1) CA3123393A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001554A1 (cg-RX-API-DMAC7.html)
IL (1) IL283920A (cg-RX-API-DMAC7.html)
MX (1) MX2021007063A (cg-RX-API-DMAC7.html)
SG (1) SG11202106344SA (cg-RX-API-DMAC7.html)
TW (1) TWI784220B (cg-RX-API-DMAC7.html)
WO (1) WO2020123900A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202104786B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022519007A (ja) * 2018-12-13 2022-03-18 オースペックス ファーマシューティカルズ インコーポレイテッド 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン
US20240197714A1 (en) * 2021-04-15 2024-06-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
JP2024514873A (ja) * 2021-04-15 2024-04-03 ニューロクライン バイオサイエンシーズ,インコーポレイテッド デューテトラベナジンおよびcyp2d6阻害剤の併用投与のための方法
WO2024090922A1 (ko) 2022-10-24 2024-05-02 주식회사 디자인셀 줄기세포 배양액 및 상기로부터 분리된 세포외소포를 유효성분으로 포함하는 뇌신경계 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ591615A (en) * 2008-09-18 2012-07-27 Auspex Pharmaceuticals Inc Benzoquinoline inhibitors of vesicular monoamine transporter 2
AU2015200243B2 (en) * 2009-06-24 2016-09-29 Egalet Ltd Controlled release formulations
US20120003330A1 (en) * 2010-06-01 2012-01-05 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
JP6362601B2 (ja) 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドAuspex Pharmaceuticals, Inc. 小胞モノアミン輸送体2の重水素化ベンゾキノリン阻害剤の製剤薬物動態
PL3265085T3 (pl) * 2015-03-06 2022-11-07 Auspex Pharmaceuticals, Inc. Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi
TWI772382B (zh) * 2017-03-15 2022-08-01 美商奧斯拜客斯製藥有限公司 氘代丁苯那嗪(deutetrabenazine)之類似物、其製備方法及用途
JP2022519007A (ja) * 2018-12-13 2022-03-18 オースペックス ファーマシューティカルズ インコーポレイテッド 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン

Also Published As

Publication number Publication date
BR112021011386A2 (pt) 2021-08-31
EP3893876A1 (en) 2021-10-20
JP2022519007A (ja) 2022-03-18
US11324732B2 (en) 2022-05-10
CA3123393A1 (en) 2020-06-18
ZA202104786B (en) 2023-12-20
CN113395966A (zh) 2021-09-14
TWI784220B (zh) 2022-11-21
KR20210114946A (ko) 2021-09-24
US20200188371A1 (en) 2020-06-18
IL283920A (en) 2021-07-29
WO2020123900A1 (en) 2020-06-18
US20220409597A1 (en) 2022-12-29
SG11202106344SA (en) 2021-07-29
TW202034917A (zh) 2020-10-01
CL2021001554A1 (es) 2022-02-11
US20240082225A1 (en) 2024-03-14
AU2019395250A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
ZA202104786B (en) Deutetrabenazine for the treatment of dyskinesia in cerebral palsy
PH12020551427A1 (en) Epinephrine spray formulations
PH12018501330A1 (en) Methods and systems for providing stimuli to the brain
GEAP202114756A (en) Combination therapy for the treatment of cancer
EP4272839A3 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
PH12022551035A1 (en) Siglec-9 ecd fusion molecules and methods of use thereof
EP4640237A3 (en) Macrophage-based therapy for use in the treatment of acute liver injury
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2019013862A (es) Terapia de combinacion.
MX2020001727A (es) Terapia de combinacion.
MX2023007680A (es) Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina.
GB201710822D0 (en) Methods and medical uses relating to the treatment of hypoglycaemia
MY200803A (en) Mpo inhibitors for use in medicine
WO2019179823A8 (en) Lactobacillus fermentum for treating fructose-related diseases
MX2019001337A (es) Métodos para tratar y prevenir efectos secundarios por tratamiento de cáncer.
WO2020032902A3 (en) Aksolotl blastema for use in the treatment of wounds and burns
MX2019015448A (es) Metodo para la prevencion de trombosis de desviacion de la arteria sistemica a pulmonar.
MX2018011607A (es) Sultiame para el tratamiento de apnea del sueño.
PH12020551185A1 (en) Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
EA202190891A1 (ru) Композиции и способы для контролируемой стимуляции яичников
AR122244A1 (es) Métodos para el tratamiento de la discinesia en la parálisis cerebral
EA202191665A1 (ru) Дейтетрабеназин для лечения дискинезии при церебральном параличе
NZ705229A (en) Pharmaceutical formulations containing ipidacrine and their use for the treatment of disorders of potency and disorders of other forms of sexual activity
AU201813182S (en) Plantar Fasciitus Strengthening Pad
HK40065186A (en) Therapeutic agents and methods of treatment